Proper functionalization of GO with biocompatible polymers and traditional anticancer drugs is projected for antitumor and C hepatitis treatment with better therapeutic effects and reduced side effects associated to traditional anticancer drugs (campthothecin derivatives, doxorubicin, cisplatin).
Eingereicht von: Javier Pérez Quiñones, MSc
Firma/Universität: JKU University Linz – Institute of Polymer Chemistry
Kooperationspartner: JKU University Linz – Institute of Polymer Chemistry; University of Havana – Center of Biomaterials
Doxorubicin is a traditional and widely employed anticancer drug with important side effects that include life threatening conditions such as cardiomyopathy with subsequent congestive heart failure, myelosuppresion and acute bowel infection [6,16]. On the other hand, camptothecin is a potent antitumor agent with also known activity against hepatitis C virus, but its high toxicity, low aqueous solubility and reduced stability at physiological conditions have precluded its clinical use [7,8]. Then, two camptothecin derivatives (Irinotecan and Topotecan) are aproved by FDA for anticancer treatments, but their therapeutic efficiency is one order or lower than the parent drug . Therefore, it is necessary to develop novel formulations for delivery of doxorubicin and camptothecin with better therapeutic effects achieved with lower doses and reduced side effects during chemotherapy treatments. The projected GO-biopolymer-vitamins or -testosterone composites forming nanoparticles and scaffolds for tissue engineering with a controlled release of doxorubicin and camptothecin are promising candidates for antitumor treatments.
- Tacar O. et al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65: 157−170.